Nicotine normalizes increased prefrontal cortical dopamine D1 receptor binding and decreased working memory performance produced by repeated pretreatment with MK-801: A PET study in conscious monkeys

Neuropsychopharmacology

Volumn 30, Issue 12, 2005, Pages 2144-2153

  Tsukada, Hideo ^a   Miyasato, Katsumasa ^b   Nishiyama, Shingo ^a   Fukumoto, Dai ^a   Kakiuchi, Takeharu ^a   Domino, Edward F ^c  

^a HAMAMATSU PHOTONICS K K   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

11C FLB457; 11C NNC112; Monkey brain; Nicotine; PET; Prefrontal cortex; Tobacco smoking

Indexed keywords

5 (7 BENZOFURANYL) 8 CHLORO 2,3,4,5 TETRAHYDRO 7 HYDROXY 3 METHYL 1H 3 BENZAZEPINE; DIZOCILPINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; GLUTAMIC ACID; ISOREMOXIPRIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NICOTINE TARTRATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DOSE RESPONSE; DRUG EFFECT; EXTRACELLULAR FLUID; MALE; MEMORY DISORDER; MICRODIALYSIS; MONKEY; NEOCORTEX; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PREMEDICATION; PRIORITY JOURNAL; RADIOACTIVITY; RECEPTOR BINDING; WORKING MEMORY;

ANIMALS; BENZAZEPINES; BENZOFURANS; DIZOCILPINE MALEATE; DOPAMINE; DOPAMINE ANTAGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; EXTRACELLULAR SPACE; GLUTAMIC ACID; MACACA MULATTA; MAGNETIC RESONANCE IMAGING; MALE; MEMORY DISORDERS; MEMORY, SHORT-TERM; MICRODIALYSIS; NICOTINE; NICOTINIC AGONISTS; POSITRON-EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PYRROLIDINES; RECEPTORS, DOPAMINE D1; SALICYLAMIDES;

EID: 27844541792     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300745     Document Type: Article

References (80)

1. Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M et al (1998). Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiat 155: 761-767.
2. 11C]NNC112 in humans: validation and reproducibility. J Cereb Blood Flow Metab 20: 225-243.
3. 1 receptors and working memory in schizophrenia. J Neurosci 22: 3708-3719.
4. 1 receptors and the pathology of schizophrenia. Neuroscientist 9: 404-416.
5. Abi-Dargham A, Narendran R, Frankle G, Khenissi L, Gil R, Cooper T et al (2003). PET imaging of prefrontal dopamine D1 receptors in chronic PCP/ketamine human abusers: a model for schizophrenia. Sci Abst, Am Coll Neuropsychopharmacol p. 3.
6. Berman KP, Meyer-Lindenberg A (2004). Functional brain imaging studies in schizophrenia. In: Charney DS, Nestler EJ (eds). Neurobiology of Mental Illness, 2nd edn. Oxford University Press: New York. pp 311-323 (Chapter 23).
7. Brier A, Su T-P, Sauders R, Carson RE, Kolachana BS, DeBartolomeis A et al (1997). Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 94: 2569-2574.
8. Brown S, Inskip H, Barraclough B (2000). Causes of excess mortality in schizophrenia. Br J Psychiat 177: 212-217.
9. Cho GA, Lewis DA (2004). The neurobiology of schizophrenia. In: Charney DS, Nestler EJ (eds). Neurobiology of Mental Illness, 2nd edn. Oxford University Press: New York. pp 299-310.
10. Clarke PBS, Fu DS, Jakubovic A, Fibiger HC (1988). Evidence that mesolimbic dopaminergic activation underlies the locomotor stimulant action of nicotine in animals. J Pharmacol Exp Ther 246: 701-708.
11. Corrigall WA, Franklin KBJ, Coen KM, Clarke PBS (1992). The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology 107: 285-289.
12. 3H]haloperidol. Life Sci 17: 993-1002.
13. Crooks PA, Dwoskin LP (1997). Contribution of CNS nicotine metabolites to the neuropharmacological effects of nicotine and tobacco smoking. Biochem Pharmacol 54: 743-753.
14. Dalack BW, Healy DJ, Meador-Woodruff JH (1998). Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. Am J Psychiat 1555: 1490-1501.
15. Damsma G, Day J, Fibiger HC (1989). Lack of tolerance to nicotine-induced dopamine release in the nucleus accumbens. Eur J Pharmacol 168: 363-368.
16. Davis KL, Kahn RS, Ko G, Davidson M (1991). Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiat 148: 1474-1486.
17. Di Chiara G, Imperato A (1988). Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving animals. Proc Natl Acad Sci USA 85: 5274-5278.
18. Dingledine R, Borges K, Bowie D, Traynelis SF (1999). The glutamate receptor ion channels. Pharmacol Rev 51: 7-61.
19. Domino EF, Mirzoyan D, Tsukada H (2004). N-methyl-D-aspartate antagonists as drug models of schizophrenia: a surprising link to tobacco smoking. Prog Neuropsychopharmacol Biol Psychiat 28: 801-811.
20. Drew AE, Derbez AE, Werling LL (2000). Nicotine receptor-mediated regulation of dopamine transporter activity in rat prefrontal cortex. Synapse 38: 10-16.
21. Dursun S, Kutcher S (1999). Smoking, nicotine and psychiatric disorders: evidence for therapeutic role, controversies and implications for future research. Med Hypotheses 52: 101-109.
22. Fagg GE (1987). Phencyclidine and related drugs bind to the activated N-methyl-D-aspartate receptor-channels complex in rat brain membranes. Neurosci Lett 76: 221-227.
23. Fowler J, Volkow N, Wang G, Pappas N, Logan J, MacGregor R et al (1996). Inhibition of monoamine oxidase in the brains of smokers. Nature 379: 733-736.
24. Fowler J, Volkow N, Wang G, Pappas N, Logan J, MacGregor R et al (1998). Neuropharmacological actions of cigarette smoke: brain monoamine oxidase B (MAO B) inhibition. J Addict Dis 17: 23-24.
25. Fuxe K, Andersson K, Harfstrand A, Agnati LF (1986). Increases in dopamine utilization in certain limbic dopamine terminal populations after a short period of intermittent exposure of male rats to tobacco smoke. J Neural Transm 67: 15-29.
26. Gardner EL (1997). Brain reward mechanisms. In: Lowinson JH, Ruiz P, Millmna RB, Langrod JG (eds). Substance Abuse: A Comprehensive Textbook, 3rd edn. Williams and Wilkins: Baltimore. pp 51-85.
27. Glassman AH (1993). Cigarette smoking implications of psychiatric illness. Am J Psychiat 150: 546-553.
28. Goff DC, Henderson DC, Amico E (1992). Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Am J Psychiat 149: 1180-1194.
29. Goldman PS (1971). Functional development of the prefrontal cortex in early life and the problem of neuronal plasticity. Exp Neurol 32: 366-387.
30. Goldman-Rakic PS (1994). Working memory dysfunction in schizophrenia. J Neuropsychiat 6: 348-357.
31. 3H- raclopride. J Neural Transm 73: 7-21.
32. 2 dopamine receptors. J Nucl Med 36: 1275-1281.
33. 1-dopamine receptors. J Nucl Med 39: 2061-2068.
34. 1a receptor agonist, inhibits amphetamine-induced dopamine release in rat striatum and nucleus accumbens. Eur J Pharmacol 287: 179-184.
35. Imperato A, Mulas A, Di Chiara G (1986). Nicotine preferentially stimulates dopamine release in the limbic system of the freely moving rat. Eur J Pharmacol 132: 337-338.
36. Inoue M, Mikami A, Ando I, Tsukada H (2004). Functional brain mapping of the macaque related to spatial working memory as revealed by PET. Cereb Cortex 14: 109-116.
37. 2 agonists and antagonists. Eur J Pharmacol 346: 189-196.
38. Javitt DC, Zukin SR (1991). Recent advances in phencyclidine model of schizophrenia. Am J Psychiat 148: 1301-1308.
39. Jentsch JD, Roth RH (1999). The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20: 201-225.
40. Johnson KM, Jones SM (1990). Neuropharmacology of phencyclidine: basic mechanisms and therapeutic potential. Annu Rev Pharmacol Toxicol 30: 707-750.
41. Kino M, Yamato T, Aomine M (2004). Simultaneous measurement of nitric oxide, blood glucose, and monoamines in the hippocampus of diabetic rat: an in vivo microdialysis study. Neurochem Int 44: 65-73.
42. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD et al (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptional, cognitive and neuroendocrine response. Arch Gen Psychiat 51: 199-214.
43. Lammertsma A, Hume S (1996). Simplified reference tissue model for PET receptor studies. Neuroimage 4: 153-158.
44. Laruelle M (2000). Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 20: 423-451.
45. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J et al (1996). Single-photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 93: 9235-9240.
46. Laruelle M, Kegeles LS, Abi-Dargham A (2003). Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. Ann NY Acad Sci 1003: 138-158.
47. Levin ED, Wilson W, Rose JE, McEvoy J (1997). Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology 15: 429-436.
48. 2 receptors in the cerebral cortex: distribution and pharmacological characterization with [3 H]raclopride. Proc Natl Acad Sci USA 86: 6412-6416.
49. 11C]DOPA and PET. Biol Psychiat 46: 681-688.
50. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelly R (1959). Study of a new schizophrenomimetic drug - Sernyl. Arch Neurol Psychiat 81: 363-369.
51. Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D et al (1996). NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 14: 301-307.
52. Marshall DL, Redfern PH, Wonnacott S (1995). Presynaptic nicotinic modulation of dopamine release in the three ascending pathways studied by in vivo microdialysis: comparison of naive and chronic nicotine-treated rats. J Neurochem 68: 1511-1519.
53. Matherson E, O'Shea B (1984). Smoking and malignancy in schizophrenia. Br J Psychiat 145: 429-432.
54. 2 receptors may modulate the function of the striatal transporter for dopamine: kinetic evidence from studies in vitro and in vivo. J Neurochem 61: 764-767.
55. Moriyoshi K, Masu M, Ishii T, Shigemoto R, Mizuno N, Nakanishi S (1991). Molecular cloning and characterization of the rat NMDA receptor. Nature B 354: 31-37.
56. Nisell M, Nomikos GG, Svensson TH (1994a). Systemic nicotine-induced dopamine release in the rat nucleus accumbens is regulated by nicotinic receptors in the ventral tegmental area. Synapse 16: 36-44.
57. Nisell M, Nomikos GG, Svensson TH (1994b). Infusion of nicotine in the ventral tegmental area or the nucleus accumbens differentially affects accumbal dopamine release. Pharmacol Toxicol 75: 348-352.
58. Nisell M, Nomikos GG, Svensson TH (1995). Nicotine dependence, midbrain dopamine systems and psychiatric disorders. Pharmacol Toxicol 76: 157-162.
59. 11C]FLB 457 binding measured by PET. Synapse 41: 87-95.
60. 1 receptors in schizophrenia revealed by PET. Nature 386: 634-636.
61. 11C-methylspiperone binding in vivo: positron emission tomography study using conscious rhesus monkeys. Brain Res 663: 191-198.
62. Pontieri FE, Tanda G, Orzi F, Di Chiara G (1997). Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 382: 255-257.
63. Sawaguchi T, Goldman-Rakic PS (1991). D1 dopamine receptors in prefrontal cortex: involvement in working memory. Science 251: 947-950.
64. Singer G, Wallace W, Hall R (1982). Effects of dopaminergic nucleus accumbens lesions on the acquisition of schedule induced self injection of nicotine in the rat. Pharmacol Biochem Behav 17: 579-581.
65. Smiley JF, Goldman-Rakic PS (1993). Heterogeneous targets of dopamine synapses in monkey prefrontal cortex demonstrated by serial section electron microscopy: a laminar analysis using the silver-enhanced diaminobenzidine sulfide (SEDS) immunolabeling technique. Cereb Cortex 3: 223-238.
66. Snyder SH (1980). Phencyclidine. Nature 285: 355-358.
67. 2 receptor binding in the anterior cingulate cortex in schizophrenia. Arch Gen Psychiat 59: 25-30.
68. Thomson AM, West DC, Lodge D (1985). An N-methyl-D-aspartate receptor-mediated synapse in rat cerebral cortex: a site of action of ketamine? Nature 313: 479-481.
69. 2 receptor availability in vivo by regulating receptor affinity induced by facilitated synaptic dopamine turnover: PET studies with microdialysis in the conscious monkey brain. J Neurosci 20: 7067-7073.
70. 11C]raclopride binding with no alterations in static dopamine concentrations in the striatal extracellular fluid in the monkey brain: multiparametric PET studies combined with microdialysis analysis. Synapse 37: 37-95.
71. 11C]raclopride binding in unanesthetized monkeys. Synapse 45: 207-212.
72. Tsukada H, Nishiyama S, Fukumoto D, Ohba H, Sato K, Kakiuchi T (2004). Effects of acute acetylcholinesterase inhibition on the cerebral cholinergic neuronal system and cognitive function: functional imaging of the conscious monkey brain using animal PET in combination with microdialysis. Synapse 52: 1-10.
73. 1 receptor binding in prefrontal cortex of conscious monkeys. Neuropsychopharmacology April 20, [E-pub ahead of print].
74. 11C]raclopride? PET studies combined with microdialysis in conscious monkeys. Brain Res 841: 160-167.
75. 11C]β-CIT-FE in the monkey brain. Synapse 42: 273-280.
76. Tsukada H, Nishiyama S, Kakiuchi T, Ohba H, Sato K, Harada N et al (1999b). Isoflurane anesthesia enhances the inhibitory effects of cocaine and GBR12909 on dopamine transporter: PET studies in combination with microdialysis in the monkey brain. Brain Res 849: 85-96.
77. Tsukada H, Nishiyama S, Ohba H, Sato K, Harada N, Kakiuchi T (2001b). Cholinergic neuronal modulations affect striatal dopamine transporter activity: PET studies in the conscious monkey brain. Synapse 42: 193-195.
78. Watanabe M, Okada H, Shimizu K, Omura T, Yoshikawa E, Kosugi T et al (1997). A high resolution animal PET scanner using compact PS-PMT detectors. IEEE Trans Nucl Sci 44: 1277-1282.
79. Weinberger DR, Berman KF, Zee RF (1986). Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I: regional cerebral blood flow evidence. Arch Gen Psychiat 43: 114-124.
80. Yamashita H, Kitayama S, Zhang Y-X, Takahashi T, Dohi T, Nakamura S (1995). Effects of nicotine on dopamine uptake in cos cells possessing the rat dopamine transporter and in PC12 cells. Biochem Pharmacol 49: 742-745.